Phase 3 trial of subcutaneous epcoritamab plus R-CHOP versus R-CHOP in patients (pts) with newly diagnosed diffuse large B-cell lymphoma (DLBCL): EPCORE DLBCL-2.

被引：0

作者：

Sehn, Laurie Helen

Chamuleau, Martine

Lenz, Georg

Clausen, Michael

Haioun, Corinne

Izutsu, Koji

Davies, Andrew John John

Zhu, Jun

Oki, Toshiko

Szafer-Glusman, Edith

Conlon, Rebekah

Chiou, Hueiyu

Ipe, David

Elliott, Brian

Wu, Jun

Salles, Gilles A.

机构：

[1] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[2] Univ British Columbia, Vancouver, BC, Canada

[3] Vrije Univ, Amsterdam Univ Med Ctr, Amsterdam, Netherlands

[4] Univ Hosp Munster, Munster, Germany

[5] Vejle Hosp, Vejle, Denmark

[6] Hop Henri Mondor, Creteil, France

[7] Natl Canc Ctr, Tokyo, Japan

[8] Univ Southampton, Southampton NIHR Canc Res UK Expt Canc Med, Southampton, Hants, England

[9] Beijing Canc Hosp, Beijing, Peoples R China

[10] AbbVie Inc, N Chicago, IL USA

[11] Genmab, Plainsboro, NJ USA

[12] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS7592

引用

页数：1